Actavis Marketed Testosterone Drug Off-Label, Ill. Jury Told
Actavis improperly marketed its testosterone replacement therapy drug Androderm and ignored safety warnings from federal regulators and studies indicating that use of such products could lead to increased risk of adverse...To view the full article, register now.
Already a subscriber? Click here to view full article